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Predictors of Hepatitis C Treatment Failure After Using 
Direct-Acting Antivirals in People Living With Human 
Immunodeficiency Virus 
Edward R. Cachay,1 Alvaro Mena,2 Luis Morano,3 Laura Benitez,4 Ivana Maida,5 Craig Ballard,6 Lucas Hill,6 Francesca Torriani,1 Angeles Castro,2  
Elena Dore,5 Sheila Castro,3 Carmen de Mendoza Fernández,4 Vicente Soriano,7 and Wm. C. Mathews1; for the HCV-TREN Cohort
1Department of Medicine, Division of Infectious Diseases, Owen Clinic, UC San Diego, California; 2Unidad de Enfermedades Infecciosas, Complejo Hospitalario Universitario de A Coruña, A 
Coruña, Spain; 3Unidad de Patología Infecciosa, Hospital Universitario Álvaro Cunqueiro, Instituto de Investigación Sanitaria Galicia Sur, Vigo, Spain; 4Servicio de Medicina Interna, Puerta de Hierro 
Research Institute and University Hospital, Madrid, Spain; 5University of Sassari, Italy; 6Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, California; 7UNIR Health Sciences 
School and La Paz University Hospital, Madrid, Spain
Background. Little is known about the influence of ongoing barriers to care in the persistence of hepatitis C virus (HCV) vi-
remia after treatment with direct-acting antivirals (DAAs) among people living with human immunodeficiency virus (PLWH).
Methods. We conducted a retrospective cohort analysis of PLWH treated through the standard of care in 3 Western countries, 
to investigate the predictors of HCV treatment failure (clinical or virologic), defined as having a detectable serum HCV ribonucleic 
acid within 12 weeks after DAA discontinuation. In addition to HCV and liver-related predictors, we collected data on ongoing illicit 
drug use, alcohol abuse, mental illness, and unstable housing. Logistic regression analyses were used to identify predictors of HCV 
treatment failure.
Results. Between January 2014 and December 2017, 784 PLWH were treated with DAA, 7% (n = 55) of whom failed HCV 
therapy: 50.9% (n = 28) had a clinical failure (discontinued DAA therapy prematurely, died, or were lost to follow-up), 47.3% (n 
= 26) had an HCV virologic failure, and 1 (1.8%) was reinfected with HCV. Ongoing drug use (odds ratio [OR] = 2.60) and mental 
illness (OR = 2.85) were independent predictors of any HCV treatment failure. Having both present explained 20% of the risk of any 
HCV treatment failure due to their interaction (OR = 7.47; P < .0001). Predictors of HCV virologic failure were ongoing illicit drug 
use (OR = 2.75) and advanced liver fibrosis (OR = 2.29).
Conclusions. People living with human immunodeficiency virus with ongoing illicit drug use, mental illness, and advanced liver 
fibrosis might benefit from enhanced DAA treatment strategies to reduce the risk of HCV treatment failure.
Keywords. DAA; drug use; HCV treatment failure; HIV; mental illness.
Real-world studies have confirmed the high efficacy and excel-
lent tolerability of direct-acting antivirals (DAAs) for the treat-
ment of hepatitis C virus (HCV) infection in people living with 
human immunodeficiency virus (PLWH). Overall, more than 
90% of PLWH treated with DAAs achieve cure [1, 2]. Hence, the 
World Health Organization proposed goals to eliminate HCV 
by 2030 [3], and the British HIV Association considered that 
HCV could be eliminated in PLWH in the United Kingdom 
by 2021 [4]. To achieve this goal, we need to decrease the pro-
portion of PLWH with ongoing HCV viremia through HCV 
screening, linkage, treatment uptake, and implementation of 
harm reduction strategies to prevent HCV reinfection. The 
causes of HCV treatment failure and resulting ongoing HCV 
viremia are different depending on whether there is virologic 
failure or premature treatment discontinuation [5].
Few studies have investigated the predictors of DAA fail-
ure among PLWH, defined as lack of sustained viral response 
(SVR), with variable results [6–8]. One study found that among 
PLWH treated with DAAs, cirrhosis status was the main clinical 
factor that decreased the chances of achieving SVR, especially 
among PLWH with CD4 counts less than 350 cells/mm3 [7]. 
Another study acknowledged that PLWH who had a baseline 
CD4 count lower than 200 cells/mm3 had lower SVR rates after 
adjusting for known HCV and liver-related predictors of HCV 
treatment response [8]. Altogether, these studies suggested that 
the impaired immune response of PLWH with low CD4 counts 
could influence their response to DAA treatment. Whether hav-
ing a low CD4 count reflects underrecognized splenic sequestra-
tion due to more advanced liver disease and portal hypertension 
or unmeasured clinical characteristics of the studied patients 
that contribute to their advanced human immunodeficiency 
virus (HIV) infection in the first place remains unclear.
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People living with HIV have a higher prevalence of illicit 
drug use, alcohol abuse, mental illness, and unstable housing 
than the HIV-uninfected population [9]. Very few studies have 
investigated the interaction of complex social and behavioral is-
sues prevalent in PLWH and their influence on DAA treatment 
outcomes [10]. Therefore, we conducted this study to investi-
gate the negative predictors of SVR among PLWH treated with 
DAA. In addition to including conventional HCV- and liver-re-
lated parameters, we investigated the effect of ongoing barriers 
to care such as illicit drug use, alcohol abuse, mental illness, and 
unstable housing in PLWH from different geographic areas.
METHODS
The Hepatitis C Virus-Transatlantic Research Network Cohort
The HCV-HIV Transatlantic Research Network (HCV-TREN) 
was implemented in March 2016, shortly after scaling-up 
DAA availability in Europe and the United States for PLWH. 
The overarching goal of this collaborative effort is to use the 
network data to inform local health policymakers on areas of 
clinical service improvement to reach HCV elimination among 
PLWH. Five academically affiliated HIV clinics in 3 different 
countries have been included. They comprise Owen Clinic at 
the University of California, San Diego (UCSD) in the United 
States, University Hospital of La Coruña in Spain, Puerta de 
Hierro Research Institute and University Hospital in Madrid, 
the University Hospital Alvaro Cunqueiro of Vigo in Spain, 
and the Hospital University of Sassari in Italy. Patients were in-
cluded in the study if they were 18 years of age or older, had 
evidence of active HCV infection, and initiated DAA treat-
ment through the local standard of care procedures between 
January 1, 2014 and December 31, 2017. The study was con-
ducted according to the principles expressed in the Declaration 
of Helsinki. Patient records/information was anonymized and 
deidentified before analysis using unique study codes generated 
at the clinics. Institutional human research protection program 
(HRPP) approval was obtained at each participating site (UCSD 
HRPP Protocol no. 171749X).
Data Collected Domains and Procedures
For this retrospective cohort study, data were primarily de-
rived from electronic medical records (EMRs). Data included 
patients’ demographics, HIV transmission risk factors, antire-
troviral therapy, CD4 cell count, and HIV viral load. We also 
collected information on HCV genotype, HCV ribonucleic acid 
(RNA) levels, prior HCV treatment history, liver fibrosis stage 
according to the modified Knodell score, cirrhosis status, his-
tory and type of prior liver decompensation, and the Model for 
End-Stage Liver Disease and Child-Turcotte-Pugh scores. Data 
collection also included (1) DAA regimen with a start and stop 
dates and (2) comorbidity burden (measured by the Charlson 
comorbidity index) [11]. For time-varying covariates, the value 
collected was the one most immediately before, but no longer 
than 3 months before the date of DAA initiation. All European 
centers conducted liver fibrosis staging using vibration-con-
trolled transient elastography (FibroScan; Echosens, Paris, 
France). At UCSD, elastography became available in 2015, and 
until then fibrosis staging was measured according to liver bi-
opsy results.
For screening of ongoing depression, self-reported illicit 
drug use, and alcohol abuse within the last 3 months of DAA 
initiation, patients completed the PHQ-9 inventory [12], the 
National Institute on Drug Abuse-Alcohol, Smoking, and 
Substance Involvement Screening Test [13], and the Alcohol 
Use Disorders Identification Test instruments [14], respectively. 
We also conducted medical record review for assessment of 
physician documentation of symptoms and risk behaviors, drug 
type, and frequency of consumption. The manual chart review 
included The Substance Abuse and Mental Health Services 
Administration clinical definition of patient self-report of 
heavy drinking as 5 or more drinks on the same occasion on 
each of 5 or more days in the past 30 days [15]. Unstable hous-
ing status was collected through diagnosis code abstraction of 
homelessness or unstable housing. We also collected from the 
chart documentation of frequent short stays (up to 2 weeks) in 
motels or different friends or family members’ houses. One site 
(Sassari) required that patients with active drug use be treated 
with DAAs only if they were on a buprenorphine or methadone 
replacement or in an institutionalized rehabilitation program. 
All other centers treated patients with ongoing drug or alcohol 
use according to their standard of care local protocols.
Having ongoing mental illness was not a contraindication for 
DAA treatment in any center. Active psychiatric illness was con-
sidered if any of the following 3 conditions were documented. 
First, a documented PHQ-9 score of 9 or higher indicative of 
ongoing depression symptoms within 3 months of starting DAA 
treatment. Second, if patients had a mental illness different than 
depression according to International Classification of Diseases 
(ICD), Tenth Revision codes, patients needed to be taking 2 
or more active psychotropic medications with medical record 
documentation of ongoing disease within 3 months of initiat-
ing DAA. Third, a documented history of psychiatric hospital-
ization or suicidal attempt within 24 weeks of DAA treatment 
initiation. Direct-acting antivirals adherence was measured 
through local pharmacy-generated medication pickup records. 
One center also relied on clinical pharmacists conducting pill 
count when patients came to their HCV clinical appointments.
Endpoints
The primary endpoint was the proportion of patients with HCV 
treatment failure defined as either having a detectable serum 
HCV RNA 12 weeks after the estimated date of DAA treatment 
completion or early DAA discontinuation with resulting on-
going HCV viremia in anyone that took at least 1 dose of DAAs. 
Secondary outcomes included the proportion of patients with 
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HCV virologic failure, defined as having a detectable HCV 
RNA 12 weeks after ending DAA treatment among those who 
completed the planned DAA treatment period, and HCV clin-
ical failure, defined as the proportion of patients who discon-
tinued DAA therapy prematurely due to any cause including 
death or loss to follow-up. Patients who were lost to follow-up 
were considered to have ongoing HCV viremia.
Statistical Analysis
Descriptive statistics were presented using (1) means with 95% 
confidence interval (CI) and frequencies and (2) percentages. 
Bivariate analyses with pairwise comparisons were conducted 
to investigate factors associated with lack of SVR. We used χ2 
test for comparison of categorical variables and 2-sided t test 
(or Wilcoxon rank-sum test) for normally (or nonnormally) 
distributed numerical variables. To fit parsimonious predic-
tion models for the primary and secondary outcomes, those 
covariates associated with the outcomes in bivariate analyses (P 
≤ .1) were entered into backward stepwise logistic regression 
models (probability of removal = 0.05). Model discrimination 
was assessed using receiver operating characteristic area, and 
model calibration was evaluated using the Hosmer-Lemeshow 
χ2 statistic. Potential predictors of DAA treatment failure in-
cluded demographics, HIV regimen, CD4, and viral load, 
HCV-genotype, prior HCV treatment history, HCV viral load, 
DAA regimen used, fibrosis stage, cirrhosis, prior liver decom-
pensation history, Charlson comorbidity index, active alcohol 
abuse, any illicit drug use, intravenous drug use (IDU), un-
stable housing, and active mental illness. Effects are presented 
as odds ratios (ORs) with their estimated 95% CI. We assessed 
for 2-way multiplicative interactions using the product of sig-
nificant covariates in the logistic regression models. Additive 
interactions were also investigated using the relative excess risk 
due to interaction (RERI), synergy index (SI), and attributable 
proportion due to interaction (AP) [16, 17]. Analyses were per-
formed using StataCorp 2016, Stata Statistical Software: Release 
15.1 (StataCorp, LLC, College Station, TX).
RESULTS
Patients
During the study period, 784 PLWH coinfected with HCV were 
treated with DAA in the HCV-TREN cohort. There were base-
line differences between the patient’s characteristics of partici-
pating sites (Table 1). The patients from San Diego, compared 
with the European sites, had a higher proportion of nonwhite 
subjects and men who have sex with men. Patients treated in 
Sassari (Italy) were older with a larger proportion of cirrhosis 
and a history of prior liver decompensation than the rest of the 
cohort. Hepatitis C virus genotype 1 infection was the most 
frequent at all sites (70.8%), but genotype 4 was infrequent 
in San Diego in contrast to some European sites. The overall 
prevalence of ongoing alcohol abuse, illicit drug use, unstable 
housing, and mental illness at the time of DAA initiation in the 
entire cohort (784 patients) was 30% (235 patients), 26.1% (205 
patients of whom 68 were IDU), 9.7% (75 patients), and 27.9% 
(219 patients), respectively.
Hepatitis C Virus Treatment Outcomes
A total of 92.9% of patients (729 of 784) experienced SVR, in-
cluding 91.4% of cirrhotics (225 of 245 patients) and 90% of 
those with prior liver decompensation (40 of 45 patients). Most 
patients with ongoing barriers to care achieved SVR, including 
90.6% with ongoing alcohol abuse (213 of 235 patients), 85.9% 
with any drug use (176 of 205 patients), 82.4% of IDU (56 of 68 
patients), 85.8% with mental illness (188 of 219 patients), and 
85.5% with unstable housing (65 of 76 patients). The propor-
tion of SVR did not differ significantly among patients treated 
at the participating clinics and was independent of the DAA 
regimen used. The SVR for HCV genotypes 1, 2, 3, and 4 were 
92.3% (512 of 555 patients), 94.4% (17 of 18 patients), 92.7% 
(89 of 96 patients), and 96.5% (111 of 115 patients), respectively.
Seven percent of patients (55 of 784) did not achieve SVR. 
Among them, 47.3% had an HCV virologic failure (26 of 55 
patients), 50.9% had a clinical failure (28 of 55 patients dis-
continued DAA therapy prematurely, died, or were lost to fol-
low-up), and 1.8% was reinfected with HCV (1 of 55 patients). 
Most patients (20 of 26) who suffered HCV viral relapse were 
infected with HCV genotype 1.  Eleven patients who suffered 
virologic failure had cirrhosis, including 7 who had failed prior 
interferon-containing regimens and 3 with a history of prior 
liver decompensation. All but 1 relapsed within 5 weeks of DAA 
treatment discontinuation. There were no virologic failures 
due to viral breakthrough during DAA therapy. Among the 28 
patients who interrupted DAA therapy prematurely, 22 aban-
doned therapy voluntarily, 3 discontinued due to intolerance to 
ribavirin, and 3 died (Supplementary Table 1). All patients who 
abandoned HCV therapy had pharmacy documentation of lack 
of picking up their DAAs during the second month of therapy. 
Fourteen patients who abandoned DAA therapy had subse-
quently documented ongoing HCV viremia, and 8 were lost to 
follow-up. The mortality causes of the 3 patients who died were 
advanced liver disease complications (n = 1), aspiration pneu-
monia (n = 1), and anal cancer complications (n = 1). The single 
patient who became reinfected had a detectable HCV viral load 
at week 12 of DAA discontinuation but with a different HCV 
genotype than the one before DAA initiation. He had a history 
of IDU and sex with men.
Predictors of Hepatitis C Virus Treatment Failure Using Direct-Acting 
Antivirals
In bivariate analysis, predictors of any HCV treatment failure 
included ongoing drug use (including IDU), alcohol abuse, 
mental illness, unstable housing, and advanced liver fibrosis 
(Table 2). Stepwise multivariable logistic-regression analyses 
identified ongoing drug use (OR = 2.60; 95% CI, 1.79–3.79) and 
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Table 1. Baseline Patient Characteristics and Direct-Acting Antiviral Regimens of Study Participants According to Study Sites
Covariates
San Diego, CA La Coruña, Spain Madrid, Spain Sassari, Italy Vigo, Spain
(n = 177) (n = 286) (n = 112) (n = 59) (n = 150)
DAA Regimen-Simplified, n (%)a
 Sofosbuvir plus ribavirin 11 (6.2) 3 (1.1) 1 (0.9) 1 (1.7) 0 (0)
 Sofosbuvir plus ledipasvir ± ribavirin 103 (58.2) 77 (26.9) 73 (65.2) 13 (22.0) 99 (66)
 Sofosbuvir plus simeprevir ± ribavirin 19 (10.7) 26 (9.1) 2 (1.8) 0 (0) 18 (12)
 Sofosbuvir plus daclatasvir ± ribavirin 5 (2.8) 4 (1.4) 10 (8.9) 17 (28.8) 11 (7.3)
 PrOD ± ribavirin 3 (1.7) 30 (10.5) 18 (16.1) 8 (13.6) 16 (10.7)
 Sofosbuvir plus velpatasvir ± ribavirin 24 (13.6) 90 (31.5) 0 (0) 8 (13.6) 5 (3.3)
 Ombitasvir/paritaprevir/ritonavir + ribavirin 0 (0) 10 (3.5) 7 (6.3) 0 (0) 1 (0.7)
 Grazoprevir/elbasvir 5 (2.8) 0 (0) 1 (0.9) 7 (11.9) 0 (0)
 Glecaprevir/pibrentasvir 7 (3.9) 46 (16.1) 0 (0) 5 (8.5) 0 (0)
Gender, n (%)b      
 Female 24 (13.6) 89 (31.1) 31 (27.7) 14 (23.7) 34 (22.7)
 Male 153 (86.4) 197 (68.9) 81 (72.3) 45 (76.3) 116 (77.3)
Race/Ethnicity, n (%)a      
 Nonwhite 33 (18.6) 0 (0) 0 (0) 0 (0) 0 (0)
 White 144 (81.4) 286 (100) 112 (100) 59 (100) 150 (100)
HIV Risk Factor, n (%)a      
 Men who have sex with men 43 (24.3) 19 (6.6) 9 (8.0) 0 (0) 1 (0.7)
 Heterosexual 29 (16.4) 0 (0) 10 (8.9) 4 (6.8) 40 (26.7)
 Hemophilia 4 (2.3) 5 (1.8) 1 (0.9) 0 (0) 1 (0.7)
 MSM + intravenous drug use 21 (11.9) 10 (3.5) 1 (0.9) 0 (0) 0 (0)
 Heterosexual + intravenous drug use 46 (26.0) 252 (88.1) 91 (88.3) 55 (93.2) 108 (72)
 Other 34 (19.2) 0 (0) 0 (0) 0 (0) 0 (0)
Active Alcohol, Baseline, n (%)a      
 No, 139 (78.5) 171 (59.8) 65 (58.0) 51 (86.4) 123 (82)
 Yes 38 (21.5) 115 (40.2) 47 (42.0 8 (13.6) 27 (18)
Active Illegal Drugs, Baseline, n (%)a      
 No 125 (70.6) 177 (61.9) 89 (79.5) 59 (100) 129 (86)
 Yes 52 (29.4) 109 (38.1) 23 (20.5) 0 (0) 21 (14)
Active Intravenous Drug Use, Baseline, n (%)a      
 No 170 (96.1) 249 (87.0) 109 (97.3) 59 (100) 129 (86)
 Yes 7 (3.9) 37 (13) 3 (2.7) 0 (0) 21 (14)
Unstable Housing, n (%)a      
 No 163 (92.1) 253 (88.5) 108 (96.4) 59 (100) 125 (83.3)
 Yes 14 (7.9) 33 (11.5) 4 (3.6) 0 (0) 25 (16.7)
Active Mental Illness, n (%)a      
 No 137 (77.4) 220 (76.9) 70 (62.5) 51 (86.4) 87 (58.0)
 Yes 40 (22.6) 66 (23.1) 42 (37.5) 8 (13.6) 63 (42.0)
HCV Genotype (Grouped), n (%)a      
 1/1a/1b 140 (79.1) 216 (75.5) 68 (60.7) 31 (52.5) 100 (66.7)
 2/2b 7 (4.0) 8 (2.8) 2 (1.8) 1 (1.7) 0 (0)
 3/3a/3b 23 (13.0) 30 (10.5) 12 (10.7) 14 (23.7) 17 (11.3)
 4 7 (3.9) 32 (11.2) 30 (26.8) 13 (22.1) 33 (22.0)
Fibrosis Score, n (%)a      
 F0–2 101 (57.1) 171 (59.8) 56 (50) 15 (25.4) 75 (50)
 F3–4 76 (42.9) 115 (40.2) 56 (50) 44 (74.6) 75 (50)
HCV Treatment Naive, n (%)a      
 No 49 (27.7) 131 (45.8) 34 (30.4) 16 (27.1) 37 (24.7)
 Yes 128 (72.3) 155 (54.2) 78 (69.6) 43 (72.8) 113 (75.3)
Cirrhosis, n (%)a      
 No 124 (70.1) 228 (79.7) 74 (66.1) 30 (50.9) 83 (55.3)
 Yes 53 (29.9) 58 (20.3) 38 (33.9) 29 (49.1) 67 (44.7)
History Prior Decompensation, n (%)b      
 No 162 (91.5) 275 (96.1) 103 (92.0) 52 (88.1) 142 (94.7)
 Yes 15 (8.5) 11 (3.9) 9 (8.0) 7 (11.7) 8 (5.3)
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mental illness (OR = 2.85; 95% CI, 1.26–6.41) as the only in-
dependent predictors for any HCV treatment failure. Ongoing 
drug use and mental illness were also predictors of DAA clin-
ical failure. The only factors associated with HCV virologic 
treatment failure were having advanced F3 or F4 liver fibrosis 
staging (OR = 2.29; 95% CI, 1.15–4.56) and ongoing drug use 
(Table 3). Table 4 presents estimates of effect for factorial ad-
ditive interactions between the covariates selected in the final 
stepwise models. For each outcome model, the effect of both risk 
factors together was more than twice the effect of either alone. 
Although the measures reported for additive interaction (RERI, 
AP, SI) were not significant at conventional levels, power was 
limited to detect such interactions. For the 3 outcomes mod-
eled, with 2-sided alpha = 0.05 and n = 784 patients, the post 
hoc power to detect multiplicative and additive interactions 
(RERI) was 0.58 and 0.22 for any failure, 0.24 and 0.09 for clin-
ical failure, and 0.17 and 0.09 for virologic failure, respectively.
DISCUSSION
In this international cohort of PLWH coinfected with HCV 
treated with DAAs, we observed high rates of HCV cure (93% 
overall, including 91.4% of PLWH with cirrhosis) similar to 
other real-world HCV-coinfected cohorts [18–20] and despite 
the high prevalence of ongoing barriers to care in our cohort. 
Among the 7% of patients who failed therapy, patient-related 
factors prompting premature DAA discontinuation predomi-
nated over DAA virologic failure.
The fact that patients with ongoing drug use and mental 
illness were independent predictors of DAA treatment failure 
should not be interpreted as a contraindication to treat these 
patients with DAAs, because most (above 85%) were cured of 
HCV infection. Our observation that having concurrent drug 
use and mental illness could account for 20% of HCV treat-
ment failure risk attributable to interaction reinforces similar 
observations in the HIV literature, pointing out that social con-
ditions such as ongoing drug use and psychosocial syndemics 
are associated with poor HIV treatment outcomes [21, 22]. Our 
findings also suggest that although current DAA treatments 
are as short as 8 weeks of treatment duration, these groups of 
PLWH would benefit from enhanced clinical follow-up during 
HCV therapy to maximize DAA adherence, completion, and 
treatment success through ongoing support and services.
Our results are in line with recent Italian, German, and 
Spanish HCV multicenter cohorts that found that a subset of 
PLWH with advanced liver fibrosis have higher rates of DAA 
virologic failure compared with those without cirrhosis [7, 8, 
19]. Unlike the German and Spanish cohorts that identified 
that low CD4 cell counts (<350 and <200 for the German and 
Spanish cohorts, respectively) were associated with higher 
chances of DAA virologic failure, we did not observe a negative 
effect of low CD4 counts on SVR among PLWH. Although 31% 
of participants in our cohort had CD4 counts below 350 (un-
like 17% in the German cohort), there were fewer patients with 
CD4 cell counts less than 200 compared with the prior cohorts 
(11.7% vs 15%) and thus could account in part for the observed 
differences. Unlike ours, none of the earlier cohorts reported 
the frequency of patient-related factors such as ongoing drug 
use that could also affect compliance with DAA regimens. 
Indeed, we observed that ongoing drug use was an independent 
factor of DAA failure and additive to the presence of advanced 
liver fibrosis for the risk of HCV virologic failure.
Race was not associated with DAA treatment response in our 
study, in line with results from of a pooled analysis of clinical trials 
[23]. Our finding contrast with results from studies conducted at the 
Veterans Affair (VA) healthcare system that observed that nonwhites 
participants (Black and Hispanics) had fewer odds of achieving 
SVR than white patients when treated with DAA [24, 25]. The VA 
studies included less than 4% of PLWH and noted that inadequate 
Covariates
San Diego, CA La Coruña, Spain Madrid, Spain Sassari, Italy Vigo, Spain
(n = 177) (n = 286) (n = 112) (n = 59) (n = 150)
HIV Viral Load in Copies/mL, n (%)a      
 >50 11 (6.2) 64 (22.4) 6 (5.4) 9 (15.3) 3 (2.0)
  ≤50 166 (93.8) 222 (77.6) 106 (94.6) 50 (84.8) 147 (98.0)
HCV Viral Load IU/mL, n (%)a      
 >700 000 125 (70.6) 81 (28.3) 80 (71.4) 38 (64.4) 111 (74)
 ≤700 000 52 (29.4) 205 (71.7) 32 (28.6) 21 (35.6) 39 (26)
Age (years), mean (95% CI) 50.8 (49.3–52.3) 46.3 (45.3–47.4) 51.7(50.6–52.9) 54. 2 (52.9–55.5) 51.3 (50.3–52.3)
Log10 HCV viral load, mean (95% CI) 6.1 (6.1–6.4) 5.4 (5.1–5.5) 6.1 (6.1–6.5) 6.0 (5.9–6.4) 6.2 (6.1–6.4)
Charlson Comorbidity Score, mean (95% CI) 5.5 (4.9–6.1) 8.3 (8.2–8.5) 2.3(1.9–2.7) 2.1 (1.7–2.5) 4.4 (3.9–4.7)
CD4 before DAA initiation, mean (95% CI) 558.2 (512.1–604.3) 433.9 (405.7–462.0) 603.5 (539.9–667.0) 869.3 (737.5–1001.1) 547.3 (489.9–604.8)
Abbreviations: CI, confidence interval; DAA, direct-acting antivirals; HCV, hepatitis C virus; HIV, human immunodeficiency virus; MSM, men who have sex with men; PrOD, paritaprevir/
ritonavir-ombitasvir and dasabuvir.
aP < .0001.
bP < .001.
Table 1. Continued
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Table 2. Bivariate Comparisons of Predictors of Any HCV Treatment Failure Using Direct-Acting Antivirals in People Living With HIV
Covariates
Failure No Failure Total
P Valuen = 55 (7.1%) n = 729 (92.2%) n = 784 (100%)
DAA Regimen-Simplified, n (%)
 Sofosbuvir plus ribavirin 1 (1.8) 15 (2.1) 16 (2.0) .23
 Sofosbuvir plus ledipasvir ± ribavirin 25 (44.5) 340 (46.6) 365 (46.6)  
 Sofosbuvir plus simeprevir ± ribavirin 9 (16.4) 56 (7.7) 65 (8.3)  
 Sofosbuvir plus daclatasvir ± ribavirin 5 (9.1) 42 (5.8) 47 (5.9)  
 PrOD ± RBV 2 (3.6) 73 (10.0) 75 (9.6)  
 Sofosbuvir plus velpatasvir ± ribavirin 8 (14.6) 119 (16.3) 127 (16.2)  
 Ombitasvir/paritaprevir/ritonavir + ribavirin 0 (0) 18 (2.5) 18 (2.3)  
 Grazoprevir/elbasvir 0 (0) 13 (1.8) 13 (1.7)  
 Glecaprevir/pibrentasvir 5 (9.1) 53 (7.3) 58 (7.4)  
Gender, n (%)     
 Female 8 (14.5) 184 (25.8) 192 (24.5) .08
 Male 47 (85.5) 545 (74.8) 592 (75.5)  
Race/Ethnicity, n (%)     
 Nonwhite, 3 (5.5) 30 (4.1) 33 (4.2) .63
 White 52 (94.5) 699 (95.9) 751 (95.8)  
HIV Risk Factor, n (%)     
 Men who have sex with men (MSM) 3 (5.5) 69 (9.5) 72 (9.2) .47
 Heterosexual 9 (16.4) 74 (10.2) 83 (10.6)  
 Hemophilia 1 (1.8) 10 (1.4) 11 (1.4)  
 MSM + intravenous drug use (IDU) 4 (7.3) 28 (3.8) 32 (4.1)  
 Heterosexual + IDU 36 (65.5) 516 (70.8) 552 (70.4)  
 Other 2 (3.6) 32 (4.4) 34 (4.3)  
Active Alcohol, Baseline, n (%)     
 No 33 (60.0) 516 (70.8) 549 (70.0) .09
 Yes 22 (40.0) 213 (29.2) 235 (30.0)  
Active Illegal Drugs, Baseline, n (%)     
 No 26 (47.3) 553 (75.9) 579 (73.9) <.001
 Yes 29 (52.7) 176 (24.1) 205 (26.1)  
Active Intravenous Drug Use, Baseline, n (%)     
 No 44 (78.6) 672 (92.3) 716 (91.3) <.001
 Yes 12 (21.4) 56 (7.7) 68 (8.7)  
Unstable housing, n (%) 
 No 44 (80.0) 664 (91.1) 708 (90.3) .007
 Yes 11 (20.0) 65 (8.9) 76 (9.7)  
Active Mental Illness n (%)     
 No 24 (43.6) 541 (74.2) 565 (72.1) <.001
 Yes 31 (56.4) 188 (25.8) 219 (27.9)  
HCV genotype (grouped), n (%)  
 1/1a/1b 43 (78.2) 512 (70.2) 555 (70.8) .44
 2/2b 1 (1.8) 17 (2.3) 18 (2.3)  
 3/3a/3b 7 (12.7) 89 (12.2) 96 (12.2)  
 4 4 (7.3) 111 (15.2) 115 (15.2)  
Fibrosis score, n (%)     
 F0–2 23 (41.8) 395 (54.2) 418 (53.3) .08
 F3–4 32 (58.2) 334 (45.8) 366 (46.7)  
HCV Treatment Naive, n (%)     
 No 20 (36.4) 247 (33.9) 267 (34.1) .71
 Yes 35 (63.6) 482 (66.1) 517 (65.9)  
Cirrhosis, n (%)     
 No 35 (63.6) 504 (69.1) 539 (68.8) .40
 Yes 20 (36.4) 225 (30.9) 245 (31.2)  
History of Liver Decompensation, n (%)     
 No 50 (90.9) 684 (93.8) 734 (93.6) .39
 Yes 5 (9.1) 45 (6.2) 50 (6.4)  
Cohort, n (%)     
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adherence to DAAs assessed by the medication/possession ratio mit-
igated the effect of race on SVR [25]. One reason to reconcile the 
discrepancy of the effect of race on SVR between the VA studies and 
ours is the different methods used to assess illegal drug use and men-
tal illness that are known factors that influence medication treatment 
adherence [26, 27]. The VA studies used historical ICD codes, unlike 
our study that ascertained them using screening inventories at the 
time of initiating DAA. Another reason is the difference in the dura-
tion of certain DAA regimens. Unlike the VA studies, short courses 
of DAA therapy (8 weeks) using sofosbuvir/ledipasvir were not used 
in our study because they were not recommended for treating HCV 
in PLWH. Hence, even if PLWH had imperfect DAA adherence but 
did not discontinue their therapy during their first 8 weeks of ther-
apy, the longer DAA treatment duration might have allowed them 
to increase their chances of achieving SVR. This could explain why 
the observed significant effect of race on SVR using DAA in the VA 
studies disappeared after extending sofosbuvir/ledipasvir therapy 
from 8 to 12 weeks [24, 25].
Our study has important limitations. First, we did not collect 
urine toxicology tests, and risk-behavior collection relied on 
patient self-report. Underreporting due to social desirability bias 
is a limitation of self-collected risk inventories [28]. We performed 
individual medical record review to supplement with clinically 
documented risk behaviors information, but underestimation of 
the burden of substance use in our population is possible. Second, 
we lack systematic measures of DAA adherence to correlate with 
the study outcomes. One study found that mental illness did not 
impact DAA adherence, but recent drug use was a risk factor for 
Covariates
Failure No Failure Total
P Valuen = 55 (7.1%) n = 729 (92.2%) n = 784 (100%)
 San Diego, CA 17 (30.9) 160 (22.0) 177 (22.6) .24
 La Coruña, Spain 17 (30.9) 269 (36.9) 286 (36.5)  
 Madrid, Spain 10 (18.2) 102 (14.0) 112 (14.3)  
 Sassari, Italy 1 (1.8) 58 (7.9) 59 (7.5)  
 Vigo, Spain 10 (18.2) 140 (19.2) 150 (19.1)  
HIV Viral Load in Copies/mL, n (%)     
 >50 8 (14.5) 85 (11.7) 93 (11.9) .52
 ≤50 47 (85.5) 644 (88.3) 691 (88.1)  
HCV Viral Load IU/mL, n (%)     
 >700 000 32 (58.2) 403 (55.3) 435 (55.5) .68
 ≤700 000 23 (41.8) 326 (44.7) 349 (44.5)  
CD4 Cell Count/mm3     
 0–199 5 (9.1) 86 (11.8) 91 (11.6) .83
 200–349 11 (20.0) 147 (20.2) 158 (20.2)  
 ≥ 350 39 (70.9) 496 (68.0) 535 (68.2)  
Age (years), mean (95% CI) 49.1 (46.9–51.3) 49.7 (49.1–50.2) 49.7 (49.1–50.2) .49
Log10 HCV viral load, mean (95% CI) 5.9 (5.7–6.10 5.8 (5.7–5.9) 5.8 (5.7–5.9) .48
Charlson Comorbidity Score, mean (95% CI) 5.8 (4.9–6.7) 5.6 (5.4–5.8) 5.6 (5.4–5.8) .68
CD4 before DAA initiation, mean (95% CI) 465.4 (403.8–526.9) 546.3 (521.2–571.5) 540.6 (516.8–564.5) .23
Abbreviations: CI, confidence interval; DAA, direct-acting antivirals; HCV, hepatitis C virus; HIV, human immunodeficiency virus; PrOD, paritaprevir/ritonavir-ombitasvir and dasabuvir; RBV, 
ribavirin.
Table 2. Continued
Table 3. Adjusted Odds Ratios (95% CI) for Modeled Covariates on Predictors of Hepatitis C Treatment Failure Among People Living With HIV in the HCV-
TREN Cohorta
 Covariates Any Failure Clinical Failure Virologic Failure
Ongoing Mental illness 2.85b [1.26–6.41] 2.78c [1.71–4.52]
Ongoing any drug use 2.60d [1.79–3.79] 3.13d [1.34–7.29] 2.75d [1.80–4.19]
F3/F4 liver fibrosis stage   2.29b [1.15–4.56]
ROC area 0.71 0.73 0.67
Hosmer-Lemeshow P value .72 .63 .84
Observations 784 757 755
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; HIV, human immunodeficiency virus; ROC, receiver operating characteristic; TREN, Transatlantic Research Network.
aExponentiated coefficients; 95% confidence intervals in brackets. Covariates significant at <0.10 in bivariate analysis entered stepwise backward selection model.
bP < .05.
cP < .01.
dP < .001.
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nonadherence [27]. A limitation of the few studies that measured 
DAA adherence confidently is that they relied on monitoring 
tools that may promote participants compliance [29], and patients 
who do not return adherence tools or abandoned therapy often 
are excluded from final analyses. Third, our definition of ongoing 
mental illness (except for PHQ-9 score ≥9) was not standardized. 
Many studies of mental illness and HIV outcomes have focused 
on historical psychiatric diagnosis [30], and, given the high prev-
alence of mental illness in PLWH [31], we consider that it is clini-
cally important to use a measure of disease severity ascertainment. 
Our criteria could underestimate the burden of mental illness due 
to providers underreporting in medical records. Fourth, we did 
not use phylogenetic analysis to differentiate whether patients 
with HCV virologic failure, in reality, could have been reinfected 
with HCV. In our cohort, all but 1 patient had an HCV viral 
relapse that occurred within the first 5 weeks of finishing DAA 
treatment, consistent with what others have reported that most of 
the cases of recurrent HCV viremia occurred early after stopping 
treatment [32]. Finally, the generalizability is also limited due to 
the small proportion of nonwhite patients studied in this cohort.
Our results highlight that to achieve HCV elimination in PLWH, 
it is necessary to individualize DAA treatment protocols based on 
patients’ needs using available local infrastructure [33]. A group of 
our patients would likely benefit from enhanced support and edu-
cation to finish DAA therapy successfully and facilitate harm-risk 
behavior reduction to minimize the risk of HCV reinfection [34]. 
These efforts need to emphasize interdisciplinary collaboration to 
leverage scarce resources in many healthcare settings.
CONCLUSIONS
In conclusion, we found that PLWH with complex barriers 
to care can be treated successfully with DAA. People living 
with HIV with ongoing illicit drug use and mental illness, in 
particular, and those with advanced liver fibrosis might benefit 
from enhanced DAA treatment support to prevent the risk of 
HCV treatment failure.
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